News

Forxiga (dapagliflozin) has been approved in the European Union to extend the indication for heart failure (HF) with reduced ejection fraction (HFrEF) to cover patients across the full…
Read More...

Aldeyra Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for topical ocular reproxalap, a first-in-class…
Read More...

Genenta Science, a clinical-stage biotechnology company engaged in the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, has entered into a development…
Read More...

Biogen Inc. and Sage Therapeutics, Inc. announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatment of…
Read More...

Sensei Biotherapeutics, Inc., an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, announced that it has signed a…
Read More...

Ultima Genomics, Inc. and 10x Genomics today announced a collaboration to integrate use of the 10x Genomics Chromium Single Cell Gene Expression solutions with Ultima's advanced…
Read More...

Sandoz, a global leader in off-patent (generic and biosimilar) medicines, announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA)…
Read More...

Atreca, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human…
Read More...

Gilead Sciences, Inc. announced the U.S. Food and Drug Administration (FDA) has approved Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable…
Read More...

Sepsis is a silent and mysterious killer that makes up nearly a quarter of deaths worldwide. This disease often leads to shock and multiple organ failure, and because of its enigmatic…
Read More...

Pliant Therapeutics, Inc., a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, announced that the U.S. Food…
Read More...

PharmaTher Holdings Ltd. announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation to KETARX (racemic ketamine) for the treatment of Rett…
Read More...

Purple Biotech Ltd. announced that it has entered into an agreement for the acquisition of Immunorizon Ltd., a private company developing potential multi-specific T and NK cell engager…
Read More...

Tonix Pharmaceuticals Holding Corp. announced an agreement whereby Tonix has acquired all of the assets of Healion Bio, Inc. (Healion) including its entire portfolio of next-generation…
Read More...

Karuna Therapeutics, Inc. and GFB (ABC), LLC, assignee of the Goldfinch Bio assignment estate, announced their entry into an exclusive license agreement under which Karuna will obtain…
Read More...

4D Molecular Therapeutics, a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced FDA clearance of the…
Read More...

Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model,…
Read More...

GSK plc announced that the US Food and Drug Administration (FDA) has approved Jesduvroq (daprodustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the…
Read More...

The University of Texas MD Anderson Cancer Center and Federation Bio, a biotechnology company pioneering bacterial cell therapies, announced a strategic collaboration to design and…
Read More...

Cidara Therapeutics, Inc. and WuXi XDC announced an expansion of their existing collaboration under which WuXi XDC will provide investigational new drug (IND)-enabling chemistry,…
Read More...